How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments

Current Pharmaceutical Design

Volumn 19, Issue 30, 2013, Pages 5362-5373

  Cluzeau, Thomas ^a,b,c,d   Robert, Guillaume ^a,b,c   Jacquel, Arnaud ^a,b,c   Auberger, Patrick ^a,b,c,d  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c Equipe labellisée par la Ligue Nationale Contre le Cancer 2011 2013   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Autophagy; Gene mutations; Myelodysplasic syndromes (MDS); Targeted therapy

Indexed keywords

3 DEZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; ADENOSYLHOMOCYSTEINASE INHIBITOR; AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GATAPARSEN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; LOCKED NUCLEIC ACID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NSC 207895; NUCLEOPHOSMIN; NUCLEOSIDE ANALOG; NUTLIN 3; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN P53; RETINOIC ACID; SEPANTRONIUM BROMIDE; SPC 3042; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EVI1; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASXL1 GENE; AUTOPHAGY; CELL DIFFERENTIATION; DNA CONFORMATION; DNA METHYLATION; DNA REPAIR; DRUG MECHANISM; ENHANCER REGION; EXON; GENE; GENE INACTIVATION; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA SPLICING; SERINE ARGININE RICH SPLICING FACTOR 2 GENE; SPLICEOSOME; SPLICING FACTOR 3B SUBUNIT 1 GENE; TET2 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; U2 SMALL NUCLEAR RNA AUXILIARY FACTOR GENE; ZINC FINGER RNA BINDING MOTIF AND SERINE ARGININE RICH 2 GENE;

ANTIMETABOLITES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES;

EID: 84881345577     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990334     Document Type: Review

References (115)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. The New England journal of medicine 2009; 361(19): 1872-85.
2. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81(1): 104-30.
3. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116(19): 3724-34.
4. Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry. Leukemia research 2011.
5. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109(8): 1536-42.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. British journal of haematology 1982; 51(2): 189-99.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89(6): 2079-88.
9. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20(10): 2429-40.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology 2009; 10(3): 223-32.
11. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British journal of haematology 2000; 110(3): 620-30.
12. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stemcell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28(3): 405-11.
13. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29(24): 3322-7.
14. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine 2011; 364(26): 2496-506.
15. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011; 6(2): 126-35.
16. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478(7367): 64-9.
17. Boehrer S, Ades L, Tajeddine N, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009; 28(22): 2205-18.
18. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell cycle (Georgetown, Tex 2010; 9(17): 3470-8.
19. Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012; 19(2): 65-70.
20. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28(4): 605-13.
21. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (New York, NY 2009; 324(5929): 930-5.
22. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468(7325): 839-43.
23. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23(7): 1343-5.
24. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009; 113(25): 6403-10.
25. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature genetics 2009; 41(7): 838-42.
26. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25(7): 1147-52.
27. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18(6): 553-67.
28. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70(22): 8981-7.
29. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature genetics 2010; 42(8): 722-6.
30. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature genetics 2010; 42(8): 665-7.
31. Makishima H, Jankowska AM, Tiu RV, et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24(10): 1799-804.
32. Crea F, Fornaro L, Bocci G, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 2012; 31(3-4): 753-61.
33. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British journal of haematology 2009; 145(6): 788-800.
34. Fisher CL, Pineault N, Brookes C, et al. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115(1): 38-46.
35. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005; 74: 481-514.
36. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995; 81(2): 197-205.
37. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402(6758): 187-91.
38. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. The New England journal of medicine 2010; 363(25): 2424-33. Epub 2010/11/12.
39. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25(7): 1153-8.
40. Afable MG, II, Makishima H, Sakaguchi H, et al. Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 2011; 118(21): 3566
41. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29(15): 1987-96.
42. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111(3): 1060-6.
43. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1(1): 34-42.
44. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114(13): 2733-43.
45. Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011; 20(2): 287-95.
46. Prebet T, Gore SD, Sun Z, et al. Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. ASH Annual Meeting Abstracts 2010; 116(21): 601
47. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. The New England journal of medicine 2011; 365(15): 1384-95.
48. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012; 26(5): 1137-40.
49. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119(14): 3203-10.
50. Abdel-Wahab O, Levine R. The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 2011; 20(4): 420-3.
51. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118(26): 6904-8.
52. Kaida D, Motoyoshi H, Tashiro E, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3(9): 576-83.
53. Maciejewski JP, Padgett RA. Defects in spliceosomal machinery: a new pathway of leukaemogenesis. British journal of haematology 2012. Epub 2012/05/19.
54. Muraki M, Ohkawara B, Hosoya T, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004; 279(23): 24246-54.
55. Tazi J, Durand S, Jeanteur P. The spliceosome: a novel multifaceted target for therapy. Trends Biochem Sci 2005; 30(8): 469-78.
56. Soret J, Bakkour N, Maire S, et al. Selective modification of alternative splicing by indole derivatives that target serine-argininerich protein splicing factors. Proceedings of the National Academy of Sciences of the United States of America 2005; 102(24): 8764-9.
57. Kotake Y, Sagane K, Owa T, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3(9): 570-5.
58. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. The New England journal of medicine 1993; 329(18): 1318-27.
59. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351(6326): 453-6.
60. Jonveaux P, Fenaux P, Quiquandon I, et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991; 6(12): 2243-7.
61. Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. British journal of haematology 2001; 115(2): 309-12.
62. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995; 9(3): 370-81.
63. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84(9): 3148-57.
64. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 2012; 51(12): 1086-92.
65. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29(15): 1971-9.
66. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67(17): 8014-21.
67. Kamal A, Mohammed AA, Shaik TB. p53-Mdm2 inhibitors: patent review (2009-2010). Expert Opin Ther Pat 2012; 22(2): 95-105.
68. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 2011; 10(2): 221-32.
69. Hansen JB, Fisker N, Westergaard M, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008; 7(9): 2736-45.
70. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The New England journal of medicine 2005; 352(3): 254-66.
71. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437(7055): 147-53.
72. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107(10): 4011-20.
73. Schlenk RF, Dohner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009; 94(1): 54-60.
74. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110(7): 2302-8.
75. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005; 106(2): 494-504.
76. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103(6): 2316-24.
77. Maki K, Yamagata T, Mitani K. Role of the RUNX1-EVI1 fusion gene in leukemogenesis. Cancer Sci 2008; 99(10): 1878-83.
78. Lam K, Zhang DE. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci 2012; 17: 1120-39.
79. Liu S, Li C, Bo L, Dai Y, Xiao Z, Wang J. AML1/RUNX1 fusion gene and t(5; 21)(q13; q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia and monocytosis. Cancer Genet Cytogenet 2004; 152(2): 172-4.
80. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74(1): 47-53.
81. Kaeferstein A, Krug U, Tiesmeier J, et al. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia 2003; 17(2): 343-9.
82. Helbling D, Mueller BU, Timchenko NA, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(36): 13312-7.
83. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3(2): 207-20.
84. Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84(4): 1243-8.
85. Wieser R, Schreiner U, Rieder H, et al. Interphase fluorescence in situ hybridization assay for the detection of rearrangements of the EVI-1 locus in chromosome band 3q26 in myeloid malignancies. Haematologica 2003; 88(1): 25-30.
86. Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89(9): 3937-41.
87. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 2006; 66(23): 11360-9.
88. Raza A, Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leukemia research 2004; 28(8): 791-803.
89. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106(4): 1207-9.
90. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20(11): 2067-70.
91. Constantinidou M, Chalevelakis G, Economopoulos T, et al. Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. Annals of hematology 1997; 74(1): 11-4.
92. Epling-Burnette PK, Loughran TP, Jr. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs 2010; 19(5): 689-98.
93. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Annals of hematology 2008; 87(11): 881-5.
94. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 2007; 109(10): 4158-63.
95. Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. Oncotarget 2012; 3(4): 490-501.
96. Cluzeau T, Robert G, Puissant A, et al. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell cycle (Georgetown, Tex 2011; 10(14): 2339-43.
97. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12(17): 5165-73.
98. Campas C, Lopez JM, Santidrian AF, et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003; 101(9): 3674-80.
99. Robert G, Ben Sahra I, Puissant A, et al. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 2009; 4(11): e7889.
100. Cluzeau T, Robert G, Karsenti JM, et al. Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines. ASH Annual Meeting Abstracts 2010; 116(21): 1817
101. Baylin SB. DNA methylation and gene silencing in cancer. Nature clinical practice 2005; 2 Suppl 1: S4-S11.
102. Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E, Maio M. Epigenetic remodelling of DNA in cancer. Histol Histopathol 2007; 22(12): 1413-24.
103. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26(47): 6697-714.
104. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113(6): 1315-25.
105. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100(8): 2957-64.
106. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002; 20(4): 167-76.
107. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006; 20(1): 1-13.
108. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8.
109. Hussein K, Theophile K, Busche G, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leukemia research 2010; 34(9): 1169-74.
110. Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. British journal of haematology 2011; 153(1): 24-32.
111. Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011; 39(9): 915-26+e2.
112. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19(3): 313-9.
113. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(9): 2999-3004.
114. Votavova H, Grmanova M, Dostalova Merkerova M, et al. Differential expression of microRNAs in CD34+ cells of 5q-syndrome. J Hematol Oncol 2011; 4: 1.
115. Meng Y, Xia Q, Hu J. Promoter Methylation and Decreased Expression of Mir-124 In Myelodysplastic Syndromes. ASH Annual Meeting Abstracts 2010; 116(21): 4014